Amgen To Present At The Oppenheimer 31st Annual Healthcare Conference

Rhea-AI Summary

Amgen (NASDAQ:AMGN) will present at the virtual Oppenheimer 31st Annual Healthcare Conference on March 16, 2021, at 2:30 p.m. ET. David M. Reese, M.D., Amgen's executive vice president of Research and Development, will lead the presentation. Interested parties can access the live audio broadcast via Amgen's website along with other investor and medical conference presentations. The event's webcast will be archived for 90 days. Amgen focuses on developing innovative therapeutics to address serious medical needs, utilizing advanced human genetics to enhance health outcomes.

THOUSAND OAKS, Calif., March 11, 2021 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the virtual Oppenheimer 31st Annual Healthcare Conference at 2:30 p.m. ET on Tuesday, March 16, 2021. David M. Reese, M.D., executive vice president of Research and Development at Amgen will present at the conference. Live audio of the conference call will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public.

The webcast, as with other selected presentations regarding developments in Amgen's business given at certain investor and medical conferences, can be accessed on Amgen's website, www.amgen.com, under Investors. Information regarding presentation times, webcast availability and webcast links are noted on Amgen's Investor Relations Events Calendar. The webcast will be archived and available for replay for at least 90 days after the event.

About Amgen 
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.  

Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.  

For more information, visit www.amgen.com and follow us on www.twitter.com/amgen.  

CONTACT: Amgen, Thousand Oaks 
Megan Fox, 805-447-1423 (media)
Trish Rowland, 805-447-5631 (media) 
Arvind Sood, 805-447-1060 (investors) 

View original content to download multimedia:http://www.prnewswire.com/news-releases/amgen-to-present-at-the-oppenheimer-31st-annual-healthcare-conference-301246017.html

SOURCE Amgen

FAQ

When is Amgen's presentation at the Oppenheimer 31st Annual Healthcare Conference?

Amgen's presentation is on March 16, 2021, at 2:30 p.m. ET.

Who will present at the Oppenheimer 31st Annual Healthcare Conference for Amgen?

David M. Reese, M.D., executive vice president of Research and Development, will present.

How can I access Amgen's presentation at the Oppenheimer conference?

The presentation can be accessed live on Amgen's website under the Investors section.

Will the Amgen Oppenheimer conference presentation be available later?

Yes, the webcast will be archived and available for replay for at least 90 days.

What focus does Amgen have in its research and development?

Amgen is committed to developing innovative human therapeutics for serious illnesses, using advanced human genetics.